Oral Cancer Diagnostics Market 2020-2024: Report to Share Key Aspects of the Industry with the Details of Influence Factors

Global Oral Cancer Diagnostics Market: Information by Indication (Oral Squamous Cell Carcinoma, Oral Verrucous Carcinoma, Mucoepidermoid Carcinoma, Oral Cavity Lymphomas and others), by Diagnosis Type (Endoscopy, Biopsy, X-Ray and Computed Tomography (CT), Positron Emission Tomography (PET), Magnetic Resonance Imaging (MRI), Ultrasonography, Fluorescence Imaging and others), by End User (Hospitals and Clinics, Research and Academic Institutes and others) and by Region (Americas, Europe, Asia-Pacific and Middle East & Africa) – Forecast till 2024

Download Sample of This Strategic Report- https://www.kennethresearch.com/sample-request-10159236


The Global Oral Cancer Diagnostics Market is expected to register a CAGR of 6.94% to reach USD 7,367.90 Million till 2024. Oral cancer is a broad category that includes a number of conditions such as cancers of lips, tongue, cheeks, hard and soft palate, the floor of the mouth, pharynx, and sinuses. Early diagnosis of oral cancer is extremely crucial as the treatment of the disease is dependent on the stage of cancer, and earlier the diagnosis, the easier it is to treat the cancerous growth.

The increase in population suffering from oral cancer, rise in the adoption rate of effective diagnostic aids for the detection of oral cancer coupled with the advances in research, and rise in risk factors that lead to cancer are expected to enhance the market growth. However, the shortage of trained professionals and the unaffordability of healthcare organizations to purchase new imaging systems is projected to curb the growth of the market.

Market Dynamics

Oral cancer diagnostics have been gaining significance in recent years owing to the rising incidence of oral cancer. According to the data published in 2017 by the National Institutes of Health (NIH), an estimated 3,70,309 people were living with oral cavity and pharynx cancer in the US in 2016. According to the same source, the oral and pharynx cancer account for 3% of all newly reported cancer cases in the US annually. Thus, the growing prevalence of oral cancer globally has led to an increased usage of diagnostic tools, which thereby provides a favorable scenario for the market to grow during the forecast period.

Download Sample of This Strategic Report- https://www.kennethresearch.com/sample-request-10159236


The global oral cancer diagnostics market, by indication, has been segmented into oral squamous cell carcinoma, oral verrucous carcinoma, mucoepidermoid carcinoma (salivary gland), oral cavity lymphomas, and others. Based on diagnosis type, the oral cancer diagnostics market has been categorized into endoscopy, biopsy, X-ray, computed tomography (CT), positron emission tomography (PET), magnetic resonance imaging (MRI), ultrasonography, fluorescence imaging, and others. Based on end user, the oral cancer diagnostics market has been categorized as hospitals and clinics, research and academic institutes, and others.

Key Players

The prominent players in the global oral cancer diagnostics market are GE Healthcare (US), F. Hoffmann-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc. (US), Siemens Healthineers (Germany), Hitachi Ltd (Japan), PeriRx, LLC (US), Canon Medical Systems Corporation (Japan), Vigilant Biosciences, Inc. (US), QIAGEN (Germany), and Koninklijke Philips NV (Netherlands).

Regional Analysis

The global oral cancer diagnostics market, based on region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.The Americas is expected to hold the largest share of the global oral cancer diagnostics market. This is owing to the presence of key market players, well-developed healthcare infrastructure, growing incidence of oral cancer, and favorable reimbursement policies in the US and Canada.

The Europe market witnessed a substantial growth in the market due to increasing government support for research & development of advanced treatment procedures and devices, availability of funds for research, growing geriatric population that are susceptible to diseases such as cancer, rising cases of cancer, and increasing adoption of medical diagnostic equipment for more accurate diagnosis and treatment of cancer. As per the data published by the World Health Organization (WHO), in 2018, there were 61,885 new oral cancer cases and 24,063 deaths caused by oral cancer in Europe.

Asia-Pacific is estimated to be the fastest growing region in the global market due to the rapidly developing medical technology, presence of a huge patient population, growing awareness about cancer and diagnostic modalities, and increasing expenditure in healthcare by the government. India held a share of 34.34% in the Asia-Pacific oral cancer diagnostics market in 2018.The oral cancer diagnostics market in the Middle East & Africa is expected to grow due to the rising awareness about cancer diagnostics coupled with gradually increasing adoption of medical diagnosis modalities in the region.

Download Sample of This Strategic Report- https://www.kennethresearch.com/sample-request-10159236

Market Segmentation

Global Oral Cancer Diagnostics Market, by Indication

Oral Squamous Cell Carcinoma

Mucoepidermoid Carcinoma (Salivary Gland)

Oral Verrucous Carcinoma

Oral Cavity Lymphomas


Global Oral Cancer Diagnostics Market, by Diagnosis Type

Computed Tomography (CT) Scan

Magnetic Resonance Imaging (MRI)

Positron Emission Tomography (PET)





Fluorescence Imaging


Global Oral Cancer Diagnostics Market, by End User

Hospitals and Clinics

Research and Academic Institutes


Global Oral Cancer Diagnostics Market, by Region


North America



Latin America


Western Europe






Rest of Western Europe

Eastern Europe






South Korea

Rest of Asia-Pacific

Middle East & Africa

Middle East


Available Additional Customizations

Company Profiles of Other Key Players

Oral Cancer Diagnostics Market, Industry Trends

Recent Developments

In January 2018, GE Healthcare entered into a partnership with F. Hoffmann La Roche to develop an integrated digital oncology diagnostics platformIn January 2019, Siemens Healthineers announced the FDA clearance of Magnetom Lumina 3 Tesla (3T) magnetic resonance imaging (MRI) scannerIn October 2017, Hitachi announced that the FDA cleared the Supria True64 Computed Tomography System, the premier model within Hitachi’s Supria compact CT family, thereby expanding its products offering

Request For Full Report- https://www.kennethresearch.com/sample-request-10159236

Intended Audience

Pharmaceutical companies

Contract research manufacturing organizations

Research & development organizations

Academic institutes

About Kenneth Research:

Kenneth Research provides market research reports to different individuals, industries, associations and organizations with an aim of helping them to take prominent decisions. Our research library comprises of more than 10,000 research reports provided by more than 15 market research publishers across different industries. Our collection of market research solutions covers both macro level as well as micro level categories with relevant and suitable market research titles. As a global market research reselling firm, Kenneth Research provides significant analysis on various markets with pure business intelligence and consulting services on different industries across the globe. In addition to that, our internal research team always keep a track on the international and domestic market for any economic changes impacting the products’ demand, growth and opportunities for new and existing players.

Contact Us

Kenneth Research
Email: Sales@kennethresearch.com
Phone: +1 313 462 0609

James Bullock is a Research Expert with a demonstrated history of working in the professional training & coaching industry. Strong professional skilled in business strategy , Strategic Planning, Research Strategy, and Marketing. also have interest in new innovations and technology

Leave a Reply